[1]马宗宾 赵永辉 刘倩玲 张智文.家族性心房颤动家系携带NEXN和JPH2基因突变分析[J].心血管病学进展,2021,(7):663-666.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.021]
　MA Zongbin,ZHAO Yonghui,LIU Qianling,et al.Mutation Analysis of NEXN and JPH2 Genes in a Family with Familial Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(7):663-666.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.021]
点击复制

家族性心房颤动家系携带NEXN和JPH2基因突变分析()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年7期
页码:
663-666
栏目:
出版日期:
2021-07-25

文章信息/Info

Title:
Mutation Analysis of NEXN and JPH2 Genes in a Family with Familial Atrial Fibrillation
作者:
马宗宾 赵永辉 刘倩玲 张智文
(河南大学人民医院 河南省人民医院 华中阜外医院,河南 郑州 450003)
Author(s):
MA Zongbin; ZHAO Yonghui; LIU Qianling; ZHANG Zhiwen
?Central China Fuwai Hospital,Henan Provincial Peoples Hospital,People’s Hospital of Henan University,Zhengzhou 450003,Henan,China)
关键词:
心房颤动; 家族性; 基因检测; 基因突变
Keywords:
Atrial fibrillation; Family; Gene detection; Gene mutation
DOI:
10.16806/j.cnki.issn.1004-3934.2021.07.021
摘要:
目的 使用全外显子测序技术对收集的1例心房颤动患者家系进行致病基因筛查及突变位点分析，初步探索该基因的生物学机制。方法 采集此家族成员外周静脉血，提取基因组DNA，应用全外显子测序技术对先证者进行候选基因突变检测，发现可疑致病位点后，通过Sanger测序法在其家系成员和101例健康人群中进行验证。并使用Polyphen2、MutationTaster和Provean三种软件进行突变基因功能检测，利用Swiss-Model软件分析致病基因突变前后的蛋白质三维结构模型。结果 该家系除先证者外，4例携带NEXN c.919C>A（p.P307T）杂合变异，2例携带JPH2 c.1088G>A（p.R363H）杂合变异，先证者及其父亲同时携带以上两种突变基因，而101例健康人均未携带上述两种突变。两种突变所在区域的氨基酸序列高度保守，三种计算机预测软件预测这两种突变均为致病性突变。结论 该家系多位成员携带NEXN c.919C>A（p.P307T）杂合突变和JPH2 c.1088G>A（p.R363H）杂合突变，这两种基因变异与该家系成员心房颤动的发生密切相关，该变异可能是该家系心房颤动的致病基因突变位点。
Abstract:
Objective To screen the pathogenic gene and analyze the mutation sites in a family of patients with atrial fibrillation by full exon sequencing, and to explore the biological mechanism of the gene. Methods Genomic DNA was extracted from the peripheral venous blood of the family members, and the candidate gene mutations were detected by full exon sequencing. After the suspicious pathogenic sites were found, Sanger sequencing method was used to verify the results in the family members and 101 healthy people. Polyphen2,MutationtTaster and Provean software were used to detect the function of the mutant gene, and Swiss-Model software was used to analyze the three-dimensional structure model of the protein before and after the mutation of the pathogenic gene. Results Except for the proband,4 cases carried the NEXN c.919C>A(p.P307T) heterozygous mutation and 2 cases carried the JPH2 c.1088G>A(p.R363H) heterozygous mutation. The proband and his father carried both the above two mutant gene,while 101 healthy people did not carry the above two mutations. The amino acid sequences of the two mutations were highly conserved,and the three computer prediction software predicted that the two mutations were pathogenic. Conclusion Many members of the family carry the NEXN c.919C>A(p.P307T) heterozygous mutation and JPH2 c.1088G>A(p.R363H) heterozygous mutation,which are closely related to the occurrence of atrial fibrillation in the family members,and may be the pathogenic gene mutation site of atrial fibrillation in the family

参考文献/References:

[1]. Zhang S. Atrial fibrillation in mainland China:epidemiology and current management[J]. Heart,2009,95(13):1052.
[2]. Schnabel ＲB,Yin X,Gona P,et al. 50 year trends in atrial fibrillation prevalence,incidence,risk factors,and mortality in the Framingham Heart Study:a cohort study[J]. Lancet,2015,386(9989):154.
[3].Lubitz SA,Yin X,Fontes JD,et al．Association between familial atrial fibrillation and risk of new-onset atrial fibrillation[J]. JAMA,2010,304(20):2263.
[4].黄从新,张澍,黄德嘉,等.心房颤动:目前的认识和治疗建议-2015[J].中国心脏起搏与心电生理杂志,2015,29(5):377-434.
[5]. Hassel D,Dahme T,?Erdmann J,?et al. Nexilin mutations destabilize cardiac Z-disks and lead to dilated cardiomyopathy[J]. Nat Med,2009,15(11):1281-1288.
[6]. Wu C,Yan H,Sun JZ,et al. NEXN is a novel susceptibility gene for coronary artery disease in Han Chinese[J]. PLoS One,2013,8(12):e82135.
[7]. Wang H,Li ZH,Wang JZ,et al. Mutations in NEXN,a Z-disc gene,are associated with hypertrophic cardiomyopathy[J]. Am J Hum Genet,2010,87(5):687-693.
[8].Richards S,Aziz N,Bale SJ,et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med,2015,17(5):405-424.
[9].Nishi M,Mizushima A,Nakagawara K,et al. Characterization of human junctophilin subtype genes[J]. Biochem Biophys Res Commun,2000,273(10):920-927.
[10].李妙龄,欧贤红,李涛,等. 慢性心房颤动降低Junctophiln在心房中的表达研究[J].重庆医学,2016,45(22):3046-3048.
[11].Sabater-Molina M,Navarro M,García-Molina Sáez E,et al. Mutation in JPH2 cause dilated cardiomyopathy[J]. Clin Genet,2016,90(5):468-469.
[12].Beavers DL,Wang W,Ather S,et al. Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization[J]. J Am Coll Cardiol,2013,62(21):2010-2019.
[13].张智文,王山岭,刘静静,等. 家族性血脂异常LPL基因新突变位点分析[J].临床心血管病杂志,2020,36(8):752-754.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
　HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(7):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
　DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(7):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
　ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
　ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
　HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
　WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
　XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
　ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(7):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
　WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(7):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
　ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(7):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]

更新日期/Last Update: 2021-09-10